General Information
- Discontinued in US in 2002
Indications
- Heparin-Induced Thrombocytopenia (HIT) (see Heparin-Induced Thrombocytopenia, [[Heparin-Induced Thrombocytopenia]])
- One of the recommended agents, per Chest 2012 guidelines [MEDLINE]: however, it is not FDA approved for HIT
Pharmacology
- Factor Xa Inhibitor (see Factor Xa Inhibitors, [[Factor Xa Inhibitors]])
- Half-Life: 25 hrs
- Metabolism: renal
Administration
- IV
- SQ
Adverse Effects
Hemorrhagic Adverse Effects
- Diffuse Alveolar Hemorrhage (DAH) (see Diffuse Alveolar Hemorrhage, [[Diffuse Alveolar Hemorrhage]]
- Gastrointestinal Hemorrhage (see Gastrointestinal Hemorrhage, [[Gastrointestinal Hemorrhage]])
- Intracerebral Hemorrhage (Hemorrhagic Cerebrovascular Accident) (see Intracerebral Hemorrhage, [[Intracerebral Hemorrhage]])
- Intracranial Epidural Hematoma (see Intracranial Epidural Hematoma, [[Intracranial Epidural Hematoma]])
- Spinal Epidural Hematoma (see Spinal Epidural Hematoma, [[Spinal Epidural Hematoma]])
- Subarachnoid Hemorrhage (SAH) (see Subarachnoid Hemorrhage, [[Subarachnoid Hemorrhage]])
- Subdural Hematoma (SDH) (see Subdural Hematoma, [[Subdural Hematoma]])
Other Adverse Effects
- xxx
- xxx
References
- xxxx